• +1-646-491-9876
    • +91-20-67278686

    Search

    T Cell Surface Glycoprotein CD4-Pipeline Review H1 2017

    T Cell Surface Glycoprotein CD4-Pipeline Review H1 2017

    • Report Code ID: RW0001834453
    • Category Pharmaceuticals
    • No. of Pages 74
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'T Cell Surface Glycoprotein CD4 - Pipeline Review, H1 2017'; T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 20 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu.

    The report 'T Cell Surface Glycoprotein CD4 - Pipeline Review, H1 2017' outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviewsalso reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 7 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Metabolic Disorders and Undisclosed which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS) , Encephalitis, Graft Versus Host Disease (GVHD) , Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Severe Acute Respiratory Syndrome (SARS) , Simplexvirus (HSV) Infections, Smallpox, Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes) , Unspecified and West Nile Virus Infections.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
    - The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
    - The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development
    Biotest AG
    CEL-SCI Corp
    Fountain Biopharma Inc
    Immupharma Plc
    Inovio Pharmaceuticals Inc
    TaiMed Biologics Inc
    United Biomedical Inc
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles
    3BNC-117 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEL-1000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    forigerimod acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HIV vaccine 2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ibalizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ibalizumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-48U1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MAX-16H5 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Target CD4 and CD8 for Type 1 Diabetes - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    N-6 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Proteins for Immunology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate CD4 for HIV - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Target CD4 for HIV - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TMB-358 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TMB-360 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tregalizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    UB-421 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VRC-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products
    T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones
    Featured News & Press Releases
    May 17, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study
    May 03, 2017: Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
    Apr 25, 2017: United BioPharma selects GE Healthcare's FlexFactory to build late-stage clinical and commercial production capacity for biopharmaceuticals
    Mar 02, 2017: Findings published in Nature Communications show that mRNA-LNP encoding a neutralizing antibody protect humanized mice from HIV challenge
    Feb 15, 2017: Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
    Feb 14, 2017: Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
    Jan 25, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study Full Analysis of Patient Recruitment
    Jan 17, 2017: Theratechnologies Ibalizumab 24-Week Pivotal Phase III Study Results Accepted as a Late Breaker Will Be Presented at CROI 2017
    Dec 22, 2016: ImmuPharma Provides Update on Lupuzor Pivotal Phase III Study
    Nov 10, 2016: Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab
    Nov 09, 2016: Antibody VRC01 Safe, Only Modest Effect in Controlling HIV Without Antiretroviral Therapy
    Nov 02, 2016: Market Studies on Ibalizumab for the United States Market
    Nov 01, 2016: Theratechnologies Announces Update from its Healthcare Analyst Day Meeting
    Oct 28, 2016: Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016
    Oct 24, 2016: Theratechnologies Announces End of Patient Treatment for Phase III Ibalizumab Trial
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Biotest AG, H1 2017
    Pipeline by CEL-SCI Corp, H1 2017
    Pipeline by Fountain Biopharma Inc, H1 2017
    Pipeline by Immupharma Plc, H1 2017
    Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Pipeline by TaiMed Biologics Inc, H1 2017
    Pipeline by United Biomedical Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Biotest AG
    CEL-SCI Corp
    Fountain Biopharma Inc
    Immupharma Plc
    Inovio Pharmaceuticals Inc
    TaiMed Biologics Inc
    United Biomedical Inc

    Request for Sample

    Report Url https://www.reportsweb.com//t-cell-surface-glycoprotein-cd4-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//t-cell-surface-glycoprotein-cd4-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//t-cell-surface-glycoprotein-cd4-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments